Antimicrobial Resistance of S. aureus Isolated from Infants with Skin and Soft Tissue Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(4):356-361

​ Reshedko G.K., Avdeeva T.G., Stunzhas O.S., Ivanchik N.V.
infants skin and soft tissue infections S. aureus susceptibility antimicrobial therapy
Section
Personal Experience
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(4):356-361

Abstract

The most common pathogens of skin and soft tissue infections (SSTI) as well as pharmacodynamics parameters of different antimicrobials against S. aureus are considered in this paper. A total of 80 clinical S. aureus isolates obtained from children (0 to 3 years of age) with SSTI in Smolensk outpatient clinics during 2006–2008 were tested. Susceptibility testing was performed by agar dilution method using the following antimicrobial agents: fusidic acid, gentamicin, mupirocin, ciprofloxacin, levofloxacin, erythromycin, clindamycin, lincomycin, tetracycline, chloramphenicol, co-trimoxazole, vancomycin, linezolid, rifampicin, oxacillin, netilmicin. The most in vitro active antimicrobials (susceptibility 100%) were linezolid, vancomycin, mupirocin, fusidic acid, netilmicin, and co-trimoxazole. High resistance rates among tested S. aureus isolates were observed for ciprofloxacin (32%), tetracycline (31%), chloramphenicol (26.5%), clindamycin (21%), erythromycin (26%), gentamicin (16%), and levofloxacin (16%). Incidence of methicillin-resistant S. aureus (MRSA) was 16%. Based on the susceptibility testing results, appropriate antimicrobials for empiric therapy of infants with SSTI in outpatient settings were proposed.

  • 1. O’Brien F., Pearman J., Gracey M., Riley T., Grubb W. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999; 37:2858-62.
  • 2. Каламкарян А.А., Архангельская Е.И., Глухенький Б.Т., Масюкова С.А. Кожные и венерические болезни. Под редакцией Скрипкина Ю.К., Мордовцева В.Н. 2-е изд. Москва: Медицина; 1999. Т. 1. с. 213-57.
  • 3. Trilla A., Miro J.M. Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. J Chemother 1995; 7 (Suppl 3):37-43.
  • 4. Mandell L.A. In: Mandell G.L., Bennett J.E., Raphael D., editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston; 2000. p. 306-7.
  • 5. Jorgensen J.H. Laboratory and epidemiologic experience with methicillin-resistant Staphylococcus aureus in the USA. Eur J Clin Microbiol 1986; 5:693-6.
  • 6. Kallen A., Driscoll T., Thornton S., Olson P., Wallace M. Increase in community-acquired methicillin-resistant Staphylococcus aureus at a naval medical center. Infect Control Hosp Epidemiol 2000; 21:223-6.
  • 7. Gosbell I.B., Mercer J.L., Neville S.A., Chant K.G., Munro R. Community-acquired, non-multiresistant oxacillinresistant Staphylococcus aureus (NORSA) in south western Sydney. Pathology 2001; 33:206-10.
  • 8. Nishijima S., Kurokawa I. Antimicrobial resistance of Staphylococcus aureus isolated from skin infections. Int J Antimicrob Agents 2002; 19:241-3.
  • 9. Guerin F., Buu-Hoi A., Mainardi J.-L., et al. Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Parisian hospital. J Clin Microbiol 2000; 38:2985-8.
  • 10. Rohani M.Y., Raudzah A., Lau M.G., et al. Susceptibility pattern of Staphylococcus aureus isolated in Malaysian hospitals. Int J Antimicrob Agents 2000; 13:209-13.
  • 11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. CLSI Document M100-S4. 2008; 22(1).
  • 12. Statement 1996 CA-SFM. Zone sizes and MIC breakpoints for non-fastidious organisms. Clin Microbiol Infect 1996; 2 (Suppl 1):46-9.
  • 13. Богданович Т.М., Страчунский Л.С. Мупироцин: уникальный антибиотик для местного применения. Клин микробиол антимикроб химиотер 1999; 1(1):57-65.
  • 14. Kochman M., Fordymacki P., Lawrynowicz-Pacior M., et al. Susceptibility to selected chemotherapeutics Staphylococcus aureus strains resistant to methicilline isolated from clinical materials in the years 1991-1992 and 1997. Med Dosw Microbiol 1999; 51:187-98.
  • 15. Perez-Fontan M., Rosales M., Rodriguez-Carmona A., Falcon T.G., Valdes F. Mupirocin resistance after longterm use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39:337-41.
  • 16. Frazee B.W., Lynn J., Charlebois E.D., Lambert L., Lowery D., Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. 2005; 45(3): 311-20.
  • 17. Swarz M.N. Use of antimicrobial agents and drug resistance. N Engl J Med 1997; 337:491-2.
  • 18. Белькова Ю.А. Фузидовая кислота в современной клинической практике. Клин микробиол антимикроб химиотер 2001; 4:324-38.
  • 19. Reynolds J.I.F., editor. Martindall the extra pharmacopoeia. 31st ed. London: Royal Pharmaceutical Society; 1996. p. 233-5.
  • 20. Turnidge J., Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents 1999; 12 (Suppl 2):35-44.
  • 21. Samra Z., Gadba R., Ofir O. Antibiotic susceptibility and phage typing of methicillin-resistant and -sensitive Staphylococcus aureus clinical isolates at the period during 1991-1997. Eur J Clin Microbiol Infect Dis 2001; 20:427-7
  • 22. O’Neill A.J., Cove J.H., Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47:647-50.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared